Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol. 2025 Jan; 43(1):75-84.
View in:
PubMed
subject areas
Adolescent
Adult
Aged
Benzamides
Female
Gene Rearrangement
Histone-Lysine N-Methyltransferase
Humans
Leukemia, Myeloid, Acute
Male
Middle Aged
Myeloid-Lymphoid Leukemia Protein
Proto-Oncogene Proteins
Spiro Compounds
Young Adult
authors with profiles
Michael J. Thirman